Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3 vs 6 Weeks Antibiotic Therapy for Diabetic Foot Osteomyelitis
NCT05074147Phase 3Withdrawn
- Sponsor
- Centre Hospitalier de Tourcoing
- Start
- May 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetic foot osteomyelitis (DFO) (2 arms), sponsored by Centre Hospitalier de Tourcoing. Primary endpoint: Percentage of treated patients achieving remission from the diabetic foot osteomyelitis at 12 months. Planned start May 2022; status: withdrawn.
02
Conditions
diabetic foot osteomyelitis (DFO)
Beyond the preview
Go deeper on NCT05074147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074147.